Taken together, our results indicated that increasing FAS expression on tumor cells by pharmacologically inhibiting KDM1A activity could improve the efficacy of L1CAM-specific CAR T cell therapy against neuroblastomas with low or heterogeneous levels of target antigen expression by unleashing antigen-independent killing via the FAS-FASL axis. Here, KDM1A is linked to neoplasm.